Markers of Toxicity and Response to Radiation Therapy in Patients With Prostate Cancer

Overview

Journal Adv Radiat Oncol

Specialty Oncology

Date 2021 Jan 25

PMID 33490732

Citations 4

Authors

Nicola J Nasser

Jonathan Klein

Abed Agbarya

Affiliations

Soon will be listed here.

Abstract

The main treatment modalities for localized prostate cancer are surgery and radiation. Surgery removes the whole prostate gland, whereas with radiation therapy the irradiated prostate remains within the patient's body. Biomarkers specific to the prostate gland should become undetectable after surgery, but this is not the case when radiation therapy is used, as residual prostate cells may still be metabolically active. Here, we review the role of tumor markers of toxicity and response to radiation therapy in patients with prostate cancer, including prostate specific antigen, human kallikrein 2, osteopontin, prostate cancer associated 3, citrulline, and others.

Citing Articles

Splice Variant of Heparanase Skipping Exon 12.

Nasser N, Nevo E, Avivi A Genes (Basel). 2024; 15(8).

PMID: 39202399 PMC: 11353719. DOI: 10.3390/genes15081039.

Quantification of biochemical PSA dynamics after radioligand therapy with [Lu]Lu-PSMA-I&T using a population pharmacokinetic/pharmacodynamic model.

Siebinga H, de Wit-van der Veen B, de Vries-Huizing D, Vogel W, Hendrikx J, Huitema A EJNMMI Phys. 2024; 11(1):39.

PMID: 38656678 PMC: 11043318. DOI: 10.1186/s40658-024-00642-2.

Review of Current Treatment Intensification Strategies for Prostate Cancer Patients.

Wasim S, Park J, Nam S, Kim J Cancers (Basel). 2023; 15(23).

PMID: 38067321 PMC: 10705205. DOI: 10.3390/cancers15235615.

Administering Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer 1-6 Days Compared to More Than 14 Days after the Start of LHRH Agonist Is Associated with Better Clinical Outcomes Due to Androgen Flare.

Nasser N, Sun K, Scanlon K, Mishra M, Molitoris J Cancers (Basel). 2022; 14(4).

PMID: 35205611 PMC: 8870394. DOI: 10.3390/cancers14040864.

References

Unal D, Tasdemir A, Oguz A, Eroglu C, Benderli Cihan Y, Turak E . Is human kallikrein-11 in gastric cancer treated with surgery and adjuvant chemoradiotherapy associated with survival?. Pathol Res Pract. 2013; 209(12):779-83. DOI: 10.1016/j.prp.2013.09.004. View

Johansson A, Lennernas B, Isacsson U . Neurovascular Bundle Infiltration Can Explain Local Relapses Using Conformal Radiotherapy of Prostate Cancer. Anticancer Res. 2017; 37(4):1825-1830. DOI: 10.21873/anticanres.11517. View

Nasser N, Nevo E, Shafat I, Ilan N, Vlodavsky I, Avivi A . Adaptive evolution of heparanase in hypoxia-tolerant Spalax: gene cloning and identification of a unique splice variant. Proc Natl Acad Sci U S A. 2005; 102(42):15161-6. PMC: 1257723. DOI: 10.1073/pnas.0507279102. View

Ciezki J, Reddy C, Garcia J, Angermeier K, Ulchaker J, Mahadevan A . PSA kinetics after prostate brachytherapy: PSA bounce phenomenon and its implications for PSA doubling time. Int J Radiat Oncol Biol Phys. 2005; 64(2):512-7. DOI: 10.1016/j.ijrobp.2005.07.960. View

Voigt J, Zappala S, Vaughan E, Wein A . The Kallikrein Panel for prostate cancer screening: its economic impact. Prostate. 2013; 74(3):250-9. DOI: 10.1002/pros.22746. View

Nagahara H, Mimori K, Utsunomiya T, Barnard G, Ohira M, Hirakawa K . Clinicopathologic and biological significance of kallikrein 6 overexpression in human gastric cancer. Clin Cancer Res. 2005; 11(19 Pt 1):6800-6. DOI: 10.1158/1078-0432.CCR-05-0943. View

Bussemakers M, van Bokhoven A, Verhaegh G, Smit F, Karthaus H, Schalken J . DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res. 1999; 59(23):5975-9. View

Nickel J . Benign prostatic hyperplasia: does prostate size matter?. Rev Urol. 2006; 5 Suppl 4:S12-7. PMC: 1502356. View

Schaefer U, Micke O, Willich N . Prostate-specific antigen (PSA) and radiotherapy in locally confined prostate cancer. Anticancer Res. 1999; 19(4A):2645-8. View

10.

Day J, Jost M, Reynolds M, Groskopf J, Rittenhouse H . PCA3: from basic molecular science to the clinical lab. Cancer Lett. 2010; 301(1):1-6. DOI: 10.1016/j.canlet.2010.10.019. View

11.

Weber G, Lett G, Haubein N . Osteopontin is a marker for cancer aggressiveness and patient survival. Br J Cancer. 2010; 103(6):861-9. PMC: 2966627. DOI: 10.1038/sj.bjc.6605834. View

12.

Annede P, Seisen T, Klotz C, Mazeron R, Maroun P, Petit C . Inflammatory bowel diseases activity in patients undergoing pelvic radiation therapy. J Gastrointest Oncol. 2017; 8(1):173-179. PMC: 5334037. DOI: 10.21037/jgo.2017.01.13. View

13.

Crook J, Gillan C, Yeung I, Austen L, McLean M, Lockwood G . PSA kinetics and PSA bounce following permanent seed prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2007; 69(2):426-33. DOI: 10.1016/j.ijrobp.2007.03.031. View

14.

Michalski J, Moughan J, Purdy J, Bosch W, Bruner D, Bahary J . Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial. JAMA Oncol. 2018; 4(6):e180039. PMC: 5885160. DOI: 10.1001/jamaoncol.2018.0039. View

15.

Drucker K, Gianinni C, Decker P, Diamandis E, Scarisbrick I . Prognostic significance of multiple kallikreins in high-grade astrocytoma. BMC Cancer. 2015; 15:565. PMC: 4521496. DOI: 10.1186/s12885-015-1566-5. View

16.

Pinkawa M, Ribbing C, Djukic V, Klotz J, Holy R, Eble M . Early hematologic changes during prostate cancer radiotherapy predictive for late urinary and bowel toxicity. Strahlenther Onkol. 2015; 191(10):771-7. DOI: 10.1007/s00066-015-0841-3. View

17.

Stagg K . Re: Prostate Cancer in Gay, Bisexual, and Other Men Who Have Sex with Men: A Review, by Simon Rosser et al. (LGBT Health 2016;3:32-41). LGBT Health. 2016; 3(3):243. DOI: 10.1089/lgbt.2016.0029. View

18.

Obiezu C, Diamandis E . Human tissue kallikrein gene family: applications in cancer. Cancer Lett. 2005; 224(1):1-22. DOI: 10.1016/j.canlet.2004.09.024. View

19.

Zelefsky M . PSA bounce versus biochemical failure following prostate brachytherapy. Nat Clin Pract Urol. 2006; 3(11):578-9. DOI: 10.1038/ncpuro0611. View

20.

Nejat R, Rashid H, Bagiella E, Katz A, Benson M . A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy. J Urol. 2000; 164(6):1891-4. View